Department of Pharmaceutics, School of Pharmacy, Shaheed Beheshti Medical Sciences University, Tehran, Iran.
Int J Pharm. 2010 Jan 4;383(1-2):7-13. doi: 10.1016/j.ijpharm.2009.08.034. Epub 2009 Sep 1.
Peritoneal carcinomatosis is a serious concern when treating digestive or ovarian tumors. Treatment with systemic chemotherapy suffers from poor penetration of cytotoxic agents into the peritoneal cavity and is not quite effective. Local delivery of drugs, especially as controlled-release delivery systems like liposomes, could provide sustained and higher drug levels and reduce systemic toxicity. In order to investigate the effect of liposome size on peritoneal retention, liposomes composed of distearoylphosphatidylcholine and cholesterol (DSPC/CHOL, molar ratio 2:1) were prepared at four sizes of 100, 400, 1000 and 3000 nm. Subsequently, these liposomes were labeled with (99m)Tc complex of hexamethylpropyleneamineoxime ((99m)Tc-HMPAO) and injected into mouse peritoneum. Then, mice were sacrificed at eight different time points and the percentage of injected radiolabel in the peritoneal cavity and the organ distribution in terms of percentage injected dose/gram tissue (%ID/g) were obtained. Results showed that the free label ((99m)Tc-HMPAO) was cleared very rapidly from the cavity so that after 5 min and 7h only 6.89+/-2.51% and 0.91+/-0.51% of the injected dose was recovered, respectively. However, for the liposomal formulations, this recovery value ranged from 8.47+/-1.62% to 29.99+/-12.06% at 7h. Peritoneal retention of the vesicles was increased with their size, and the highest retention rate was obtained with 1000 nm liposomes with an AUC value 15.51 times that of (99m)Tc-HMPAO. In blood, as expected, 100 nm liposomes showed much higher levels because of their greater stability. Their greater blood concentration also caused increased levels in the heart and kidneys, although their organ to blood AUC ratio was the lowest. Overall, among the different sized neutral liposomes investigated, the 1000 nm vesicles seemed to be the most optimal, achieving a greater peritoneal level and retention.
当治疗消化系统或卵巢肿瘤时,腹膜癌病是一个严重的问题。全身化疗治疗存在细胞毒性药物在腹腔内渗透不良的问题,效果并不理想。药物的局部给药,特别是作为脂质体等控释给药系统,可以提供持续和更高的药物水平,并降低全身毒性。为了研究脂质体大小对腹膜保留的影响,制备了由二硬脂酰基磷脂酰胆碱和胆固醇(DSPC/CHOL,摩尔比为 2:1)组成的四种大小的脂质体,分别为 100nm、400nm、1000nm 和 3000nm。随后,将这些脂质体用六甲基丙烯酰胺肟(99mTc-HMPAO)标记,并注入小鼠腹腔。然后,在八个不同时间点处死小鼠,获得腹腔内注射放射性标记的百分比和器官分布的注射剂量/克组织百分比(%ID/g)。结果表明,游离标记物(99mTc-HMPAO)从腹腔中迅速清除,以至于在 5 分钟和 7 小时时,仅回收了注射剂量的 6.89+/-2.51%和 0.91+/-0.51%。然而,对于脂质体制剂,在 7 小时时,回收值范围为 8.47+/-1.62%至 29.99+/-12.06%。囊泡的腹膜保留率随其大小增加而增加,1000nm 脂质体的保留率最高,AUC 值是 99mTc-HMPAO 的 15.51 倍。在血液中,由于其稳定性更高,100nm 脂质体显示出更高的水平。它们在血液中的浓度更高,也导致心脏和肾脏中的浓度增加,尽管它们的器官与血液 AUC 比值最低。总的来说,在所研究的不同大小的中性脂质体中,1000nm 囊泡似乎是最理想的,能够达到更高的腹膜水平和保留率。